CLEVELAND, May 29, 2012 /PRNewswire/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced NTT DATA signed a non-exclusive license to resell DATATRAK ONE™ in the Chinese market.
As an existing value-added reseller of DATATRAK ONE™ and Enterprise Transfer services within the Japanese market, NTT DATA extends its reach into China to deliver clinical trials with DATATRAK's cloud-based unified research platform. NTT DATA will be designing and delivering electronic clinical trials under this multi-year agreement. An added benefit of the strategic partnership is the ability to leverage NTT DATA's existing offices in China and experts to accelerate the penetration of the Chinese market.
"NTT DATA is proud to expand its global footprint by executing its Pan Asia strategy through the use of DATATRAK ONE™," commented Hidenori Chihara, NTT DATA's Senior Executive Manager Healthcare Division. "As evident by the attendance and content of last week's DIA meeting in Shanghai, China is becoming a dynamic emerging country in the Pharmaceutical industry. Together with DATATRAK, we are positioned to be the leader in both local and global clinical trials in China."
"This agreement creates a Pan Asian powerhouse that allows for both global companies and local Chinese companies to take advantage of our unified software suite," stated Laurence P. Birch, DATATRAK's Chairman of the Board and CEO. "We are excited about the opportunities the strategic partnership will bring as we expand the continued combination of DATATRAK's superior technology and NTT DATA's world class delivery services into the Chinese market."
DATATRAK ONE™ is a comprehensive cloud-based global clinical research platform helping customers with the strategy, planning and management of their entire life science product portfolio, including resource management, study execution needs and safety reporting.
DATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK's Clinical and Consulting Services™ group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK ONE™ software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I - Phase IV drug and devices studies in multiple languages throughout the world. DATATRAK has offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North Carolina. For more information, visit http://www.datatrak.net.
Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain of the factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's quarterly report filed with the OTCQX Market on May 10, 2012 announcing its results for the three-month period ending March 31, 2012. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.
|SOURCE DATATRAK International, Inc.|
Copyright©2010 PR Newswire.
All rights reserved